Search
                    Minnesota Paid Clinical Trials
A listing of 2107  clinical trials  in Minnesota  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            973 - 984 of 2107
        
                Minnesota is currently home to 2107 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
            
                                                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    
                
                                    DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
                                
            
            
        Recruiting
                            
            
                This is a multicenter, open-label, Phase 1 study to assess the effects of DCSZ11 as a monotherapy and in combination in patients with advanced or metastatic solid tumors. The study consists of an Escalation Phase (Phase 1a) and a Dose Expansion/Optimization Phase (Phase 1b).             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/23/2025
            
            Locations: Mayo Clinic, Rochester, Minnesota         
        
        
            Conditions: Advanced or Metastatic Solid Tumors
        
            
        
    
                
                                    Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease
                                
            
            
        Recruiting
                            
            
                The goal of this clinical trial is to test the safety of lab-grown heart cells made from stem cells in subjects with congenital heart disease. The main questions it aims to answer are:
* Is this product safe to deliver to humans
* Is the conduct of this trial feasible
Participants will be asked to:
* Agree to testing and monitoring before and after product administration
* Receive investigational product
* Agree to lifelong follow-up Researchers will compare subjects from the same pool to see...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 40 years
            Trial Updated:
                06/23/2025
            
            Locations: Mayo Clinic, Rochester, Minnesota         
        
        
            Conditions: Univentricular Heart, Congenital Heart Disease, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
        
            
        
    
                
                                    Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
                                
            
            
        Recruiting
                            
            
                PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.             
        
        
    Gender:
                ALL
            Ages:
                75 years and above
            Trial Updated:
                06/23/2025
            
            Locations: Essentia Health, Duluth, Minnesota         
        
        
            
        
    
                
                                    Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
                                
            
            
        Recruiting
                            
            
                Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF).
Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/23/2025
            
            Locations: Abbott Northwestern Hospital, Minneapolis, Minnesota         
        
        
            Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
        
            
        
    
                
                                    Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
                                
            
            
        Recruiting
                            
            
                This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF).             
        
        
    Gender:
                ALL
            Ages:
                60 years and below
            Trial Updated:
                06/23/2025
            
            Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota         
        
        
            Conditions: Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myeloproliferative Neoplasms, Myelofibrosis, Myelodysplasia, Refractory Anemia, High Risk Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large Cell Non Hodgkins Lymphoma, Lymphoblastic Lymphoma, Burkitt Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult, Multiple Myeloma, Juvenile Myelomonocytic Leukemia, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, MRD Positive Leukemia, Natural Killer Cell Malignancies, Acquired Bone Marrow Failure Syndromes
        
            
        
    
                
                                    A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
                                
            
            
        Recruiting
                            
            
                TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous T cells are engineered to express a T cell receptor that recognizes tumor-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. The purpose of this screening study is to collect samples to conduct HLA genotyping, HLA Loss of Heterozygosity (LOH) assessment, and expression of Tumor-associated Antigens (TAA) testing. These results will be used to determine if participan...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/20/2025
            
            Locations: University of Minnesota, Masonic Cancer Center, Minneapolis, Minnesota         
        
        
            Conditions: Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers, Sarcoma, Uveal Melanoma, NUT Carcinoma
        
            
        
    
                
                                    An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
                                
            
            
        Recruiting
                            
            
                The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347).
No study drug will be given during this study.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 70 years
            Trial Updated:
                06/20/2025
            
            Locations: University of Minnesota, Minneapolis, Minnesota         
        
        
            Conditions: Chronic Kidney Disease (CKD)
        
            
        
    
                
                                    Acupressure for the Reduction of Anxiety in Patients Receiving Cancer-Directed Therapy
                                
            
            
        Recruiting
                            
            
                This clinicaI trial is being done to determine if acupressure is helpful to reduce anxiety related to chemotherapy, compared with "sham" (or placebo) acupressure in patients with cancer. Anxiety, experienced by many patients with cancer, can be related to chemotherapy and may contribute to other symptoms, such as nausea and poor quality of life. Some patients diagnosed with cancer express interest in non-medicine ways to manage symptoms. Acupressure is the application of non-invasive finger pres...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/19/2025
            
            Locations: Mayo Clinic in Rochester, Rochester, Minnesota         
        
        
            Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
        
            
        
    
                
                                    Dual Implant Versus Single Implant Distal End of Femur
                                
            
            
        Recruiting
                            
            
                This research study is being conducted to examine the effect of two versus one fixation device for fixation of distal femur fractures.             
        
        
    Gender:
                ALL
            Ages:
                60 years and above
            Trial Updated:
                06/19/2025
            
            Locations: Mayo Clinic Minnesota, Rochester, Minnesota         
        
        
            Conditions: Femur Fracture
        
            
        
    
                
                                    Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve
                                
            
            
        Recruiting
                            
            
                Collect real-world data on acute and long-term safety and performance of the MITRIS RESILIA Mitral Valve, Model 11400M, in subjects requiring replacement of their native or prosthetic mitral valve with or without concomitant procedures.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/19/2025
            
            Locations: Mayo Clinic, Rochester, Rochester, Minnesota         
        
        
            Conditions: Mitral Stenosis, Mitral Valve Insufficiency
        
            
        
    
                
                                    RESPONDER-HF Trial
                                
            
            
        Recruiting
                            
            
                Multicenter, Prospective, Randomized, Sham Controlled, Double Blinded Clinical Trial, with; 1:1 randomization             
        
        
    Gender:
                ALL
            Ages:
                40 years and above
            Trial Updated:
                06/19/2025
            
            Locations: Mayo Clinic Rochester, Rochester, Minnesota         
        
        
            Conditions: Heart Failure, Heart Failure, Diastolic
        
            
        
    
                
                                    Long-Term Real-World Outcomes Study on Patients Implanted With a Neurostimulator
                                
            
            
        Recruiting
                            
            
                The REALITY study is a prospective, post-market, non-randomized, multi-center, single-arm, open-label study intended to collect short- and long-term safety and effectiveness data on various populations implanted with Abbott's neurostimulation systems.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/19/2025
            
            Locations: Nura, Edina, Minnesota         
        
        
            Conditions: Chronic Pain
        
            
        
    